LYMPHIR™ (denileukin diftitox-cxdl)
Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
ApprovedCommercial Launch
Key Facts
Indication
Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
Phase
Approved
Status
Commercial Launch
Company
About Citius Oncology
Citius Oncology is a biopharmaceutical company with a mission to develop and commercialize targeted oncology therapies by focusing on programs with potentially reduced development and clinical risks. Its defining achievement is the FDA approval of LYMPHIR™ (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma (CTCL) in August 2024, transitioning the company to a commercial entity. The core strategy involves leveraging existing clinical data, intellectual property, and regulatory exclusivity to expedite the path to market for treatments addressing high unmet medical need in oncology.
View full company profile